5th mRNA-Based Therapeutics Summit Europe

mRNA is no longer just a headline, it's transforming medicine. From BioNTech's acquisition of CureVac to the EMA's and MHRA's latest guidance on mRNA product development, and even the world's first personalised CRISPR therapy for Baby KJ, the field has reached a new level of stability while opening doors to revolutionary therapeutic and gene editing applications. Returning for its fifth year, the mRNA-Based Therapeutics Summit Europe gives you the insights and connections to turn these breakthroughs into action. The new Gene Editing Focus Day highlights how mRNA enables safer, transient editing strategies, while addressing regulatory and translational challenges. Hear directly from Moderna, AstraZeneca, CybernaX Bio, Avocet Bio, and others about clinical readiness and delivery innovations bringing therapies closer to patients. With exclusive investor presentations and a high-profile panel featuring Innosuisse, NRW.Bank, and Lukasiewicz-PORT, you'll gain candid perspectives on what makes an mRNA platform fundable in 2026, and actionable strategies to de-risk your programs and secure partnerships in today's competitive landscape. Built around case studies and never-before-seen preclinical and clinical data on mRNA delivery, stability, and next-generation modalities such as saRNA and circRNA, the summit unites 170+ senior leaders across R and D, CMC, business development, and regulation for three days of learning, networking, and collaboration to put you at the forefront of mRNA and gene editing innovation in 2026.